Clinical Trial Detail

NCT ID NCT02546284
Title Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Humanigen, Inc.
Indications

chronic myelomonocytic leukemia

Therapies

LAM-003

Age Groups: adult senior

No variant requirements are available.